Kanamycin sulfate was an aminoglycoside broad-spectrum antibiotic, whose antibacterial spectrum was similar to that of neomycin. It mainly causes serious infection of gram-negative bacteria such as escherichia coli, klebsiella, proteobacteria, pneumoniae, enterobacter pneumoniae and shigella, and has good antibacterial effect on drug-resistant staphylococcus aureus. Clinically, it is mainly used for pulmonary infection, urinary tract infection, biliary tract infection, septicemia and abdominal infection caused by sensitive bacteria. The latter two are often combined with other antibiotics. It can also be used to infect s. aureus resistant to other antibiotics but sensitive to Kanamycin sulfate. To treat TB, Kanamycin sulfate is a second-line drug.
Principle:
Kanamycin sulfate mainly binds to bacterial ribosomes for 30S subunits, inhibiting bacterial protein synthesis. In recent years, drug-resistant strains have increased significantly. Some bacteria produce aminoglycoside passivase, which makes them lose antibacterial activity. Kanamycin has complete cross resistance with streptomycin and neomycin, and partial cross resistance with other aminoglycosides.
Kanamycin sulfate mainly binds to bacterial ribosomes for 30S subunits, inhibiting bacterial protein synthesis.